Description: Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Home Page: www.rainthera.com
RAIN Technical Analysis
8000 Jarvis Avenue
Newark,
CA
94560
United States
Phone:
510 953 5559
Officers
| Name | Title |
|---|---|
| Mr. Avanish Vellanki M.B.A. | Co-Founder, CEO & Chairman |
| Dr. Robert C. Doebele M.D., Ph.D. | Co-Founder, Member of Scientific Advisory Board, Pres & Chief Scientific Officer |
| Dr. Richard P. Bryce | Exec. VP & Chief Medical Officer |
| Mr. Nelson D. Cabatuan | Sr. VP of Fin. & Admin. |
| Ms. Theresa O'Connell M.S. | Director of Corp. Devel. & Operations |
| Ms. Vijaya Tirunagaru Ph.D. | Sr. VP & Head of Research |
| Mr. Lucio Tozzi | Sr. VP of Clinical Operations |
| Ms. Buenaflor Nicolas M.P.H. | VP, Head Global Drug Safety & Pharmacovigilance |
| Dr. Nora Ku M.D. | MD & VP of Clinical Devel. |
| Dr. Mehdi Paborji Ph.D. | Sr. VP of Technical Operations |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.0259 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-04-23 |
| Fiscal Year End: | December |
| Full Time Employees: | 44 |